Anticonvulsant

NEURELIS STUDY PUBLISHED IN EPILEPSIA, A WORLD-CLASS JOURNAL DEDICATED TO EPILEPSY

Retrieved on: 
Donnerstag, Juni 9, 2022
Science, Benzodiazepine, Somnolence, Diazepam, AED, Coma, Adult, Suicidal ideation, Seizure, Headache, Research, Death, Behavior, CCMS, Food, Pharmacokinetics, Central nervous system, Depression, Contraindication, AND, Status epilepticus, Glaucoma, Benzyl alcohol, Metabolic acidosis, Therapy, Boxed warning, Hypoventilation, Multimedia, Drug, Health, Hemangioma, FDA, Intraocular pressure, Patient, Schedule, Risk, Technology, Mania, Schizophrenia, Quality of life, Diagnosis, SAN, ROCK, CNS, Anticonvulsant, Regulation of tobacco by the U.S. Food and Drug Administration, View, Safety, Pharmaceutical industry, Dietary supplement, Birth control, Medicine, Gustav Neuring, Epilepsy, G

SAN DIEGO, June 9, 2022 /PRNewswire/ -- Neurelis, Inc., announced the publication of a study recently available online in the peer-reviewed, scientific journal Epilepsia .

Key Points: 
  • SAN DIEGO, June 9, 2022 /PRNewswire/ -- Neurelis, Inc., announced the publication of a study recently available online in the peer-reviewed, scientific journal Epilepsia .
  • Epilepsia is the world's leading journal of original scientific research onmultiple aspects of epilepsy.
  • Epilepsia publishes reviews, opinion pieces, and guidelines that foster understanding and aim to improve the diagnosis and treatment of people with seizures and epilepsy.
  • "Our mission is to help patients who experience the most debilitating aspect of their epilepsy, lack of seizure control and seizure unpredictability.

CWCI Notes Changes in the Mix of California Workers’ Comp Prescription Drugs and Payments

Retrieved on: 
Mittwoch, Juni 8, 2022
Professional Services, Health, Other Professional Services, Insurance, Human Resources, Pharmaceutical, Ibuprofen, Anticonvulsant, NSAID, Fenoprofen, Formulary, Pain, Growth, Review, Anticoagulant, Plasma protein binding, Prescription, Medicaid, Ketoprofen, Institute, Naproxen, Pharmaceutical industry, Nonsteroidal anti-inflammatory drug

Updated figures from CWCIs Prescription Drug Interactive Application ranks the top 10 therapeutic drug categories in California workers comp based on the volume of prescriptions and total reimbursements.

Key Points: 
  • Updated figures from CWCIs Prescription Drug Interactive Application ranks the top 10 therapeutic drug categories in California workers comp based on the volume of prescriptions and total reimbursements.
  • Comparing the distributions of drugs dispensed from 2012 through 2021, CWCI analysts tracked how the mix of prescription drugs and drug payments in the system changed over the past decade and noted more recent trends in prescription drug utilization and reimbursement.
  • On the other hand, musculoskeletal drugs have fallen from 10.6% of all workers comp prescriptions in 2016 to 6.0% of the prescriptions last year, a drop that followed the states implementation of a workers comp formulary in 2017.
  • Thus, combined payments for these drugs, which a decade ago represented only 0.9% of the prescription drug costs, accounted for 8.1% of the total drug spend in 2021.

NEURELIS TO HIGHLIGHT VALTOCO (DIAZEPAM NASAL SPRAY) CIV DEVELOPMENT PROGRAM Updates AT 16TH EILAT CONFERENCE

Retrieved on: 
Dienstag, Mai 31, 2022
Food, Coma, Seizure, Mania, Pharmacokinetics, CNS, Conference, International League Against Epilepsy, Headache, Schizophrenia, Metabolic acidosis, Somnolence, Hemangioma, Suicidal ideation, Anticonvulsant, Hypoventilation, Depression, Boxed warning, SAN, Drug, Diazepam, Administration, Death, Science, Multimedia, Health, Patient, ROCK, Adult, Schedule, FDA, Status epilepticus, Epilepsy, Benzodiazepine, Central nervous system, AND, Therapy, Risk, CCMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AED, View, Intraocular pressure, Device, Benzyl alcohol, Contraindication, Safety, Technology, Glaucoma, Behavior, Pharmaceutical industry, Dietary supplement, Birth control, Medicine, Gustav Neuring

The VALTOCO development program included 175 patients and treated more than 4,000 seizures.

Key Points: 
  • The VALTOCO development program included 175 patients and treated more than 4,000 seizures.
  • Currently, the Stellina trial, a Phase 1/2a open-label study of VALTOCO, is investigating pharmacokinetics, safety, and tolerability in pediatric epilepsy patients ages 2 to 5.
  • For more information on Neurelis, please visit www.neurelis.com .For the latest scientific information on VALTOCO, please visit www.neurelismedicalaffairs.com .
  • For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.

Global Landau-Kleffner Syndrome (LKS) Treatment (Focal Motor Seizures, Tonic Seizures, Atonic Seizures) Market Analysis/Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Mittwoch, Mai 18, 2022
Biotechnology, Pharmaceutical, Health, Atonic seizure, Disease, Anticonvulsant, Seizure, Convulsion, Landau–Kleffner syndrome, Patient, LKS, Treatment, Speech, Speech–language pathology, Lists of diseases, Growth, Diagnosis, Pharmaceutical industry

Rapidly emerging treatment options for managing and treating the symptoms of LKS are supporting the growth of the global LKS treatment market.

Key Points: 
  • Rapidly emerging treatment options for managing and treating the symptoms of LKS are supporting the growth of the global LKS treatment market.
  • Surging demand for effective treatment and the growing number of treatment options are further accelerating the growth of the global LKS treatment market.
  • Rising health awareness among the global population and early diagnosis and effective treatment are also contributing to the growth of the global LKS treatment market.
  • To classify and forecast global LKS treatment market based on type, treatment, diagnosis, end user, region, and competitive Landscape
    To examine competitive developments such as expansions, new services, mergers & acquisitions, etc, in global LKS treatment market

NeuroPace to Present at the 2022 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Freitag, Mai 13, 2022
Responsive neurostimulation device, Patient, CEO, Anticonvulsant, Population, Conference, GLOBE, Lists of diseases, Epilepsy, Seizure, Pharmaceutical industry

MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will be participating in the upcoming 2022 RBC Capital Markets Global Healthcare Conference.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced it will be participating in the upcoming 2022 RBC Capital Markets Global Healthcare Conference.
  • Mike Favet, CEO, is scheduled to present on Tuesday, May 17 at 9:30 a.m. Eastern Time.
  • A live webcast of this event, as well as an archived recording, will be available on the Investors section of the companys website at: https://investors.neuropace.com .
  • The webcasts will be archived and available for replay for at least 90 days after the event.

NeuroPace Reports First Quarter 2022 Financial Results

Retrieved on: 
Donnerstag, Mai 12, 2022
Natural borrowing limit, Anticonvulsant, Population, U.S. Securities and Exchange Commission, Seizure, Webcast, Patient, Financial condition report, Result, Lists of diseases, COVID-19, Epilepsy, Total, Trial of the century, Awareness, Growth, Omicron, EMU, Forward-looking statement, Responsive neurostimulation device, SEC, COVID, Analysis, Annual report, GLOBE, Video game, Pharmaceutical industry

MOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending March 31, 2022.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today reported financial results for the quarter ending March 31, 2022.
  • Total revenue was $11.4 million in the first quarter of 2022, compared to $11.2 million in the prior year period.
  • Gross margin for the first quarter of 2022 was 73% compared to 76% in the first quarter of 2021.
  • Total operating expenses in the first quarter of 2022 were $18.0 million, compared with $12.4 million in the prior year period.

CLS Americas Debuts Office-Based, Fusion-Guided TRANBERG Focal Laser Ablation System at AUA 2022 Conference

Retrieved on: 
Donnerstag, Mai 12, 2022
Experience, Physician, Anticonvulsant, Company, Annual conferences, Nasdaq, Patient, Trial of the century, Clinical trial, Brain, Conference, URN, Prostate cancer, Man, AUA, Erectile dysfunction, Safety, Technology, Principle, III, CLS, Urinary incontinence, LLC, Diagnosis, GLOBE, Medical imaging, EU

IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced it will debut its Office-Based, MR/US Fusion-Guided, TRANBERG Thermal Therapy System for high precision, focal laser ablation of soft tissue, such as prostate cancer tumors, at the upcoming AUA 2022 Conference being held May 13-16, 2022 in New Orleans.

Key Points: 
  • IRVINE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CLS Americas, a subsidiary of Clinical Laserthermia Systems AB, today announced it will debut its Office-Based, MR/US Fusion-Guided, TRANBERG Thermal Therapy System for high precision, focal laser ablation of soft tissue, such as prostate cancer tumors, at the upcoming AUA 2022 Conference being held May 13-16, 2022 in New Orleans.
  • The AUA 2022 Annual Conference is the worlds premier event for physicians, clinicians, and researchers to explore the latest advancements in urologic medicine, stated Michael Magnani, president of CLS Americas.
  • CLS is pleased to introduce its Office-Based, Fusion-Guided TRANBERG Thermal Therapy System at this years conference.
  • CLS History & Experience Image-Guided, Focal Laser Ablation of Prostate Tumors
    CLSs TRANBERG Thermal Therapy System has been used in hundreds of tumor laser ablation procedures in patients with localized prostate cancer in the US and EU using an in-bore, MRI-guided procedure.

The Worldwide Cerebral Palsy Treatment Industry is Expected to Reach $4.3 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Mittwoch, Mai 11, 2022
General Health, Other Health, Health, Pharmaceutical, Managed Care, Dyskinetic cerebral palsy, Disorder, Posture, Investment, Brain, Insurance, Headache, Dizziness, Depression, Prevalence, Cerebral palsy, Confusion, Government, Lethargy, Anticonvulsant, Pharmacy, Patient, Ataxic cerebral palsy, CAGR, Research, Physical, Muscle, Growth, Awareness, Speech, Spastic cerebral palsy, Residential care

The global cerebral palsy treatment market was valued at $3,166.82 million in 2020, and is projected to reach $4,365.01 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.

Key Points: 
  • The global cerebral palsy treatment market was valued at $3,166.82 million in 2020, and is projected to reach $4,365.01 million by 2030, registering a CAGR of 3.3% from 2021 to 2030.
  • Cerebral palsy is a group of disorders that affect a person's ability to move and maintain balance and posture.
  • However, high costs associated with medications is expected to create hindrances for the growth of the cerebral palsy treatment market.
  • Based on disease type, it is classified into spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.

The Worldwide Huntington Disease Treatment Industry is Expected to Reach $1.4 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Mai 10, 2022
Biotechnology, Pharmaceutical, Health, Online, Child, COVID-19, HD, Chorea, Prevalence, Hospital, Disorder, Neurodegeneration, HTT, Pharmacy Council of India, FDA, Family, Health status of Asian Americans, Incidence, CAG, Huntington's disease, R, SOM Biotech, Anticonvulsant, Pharmacy, Lists of diseases, SOM, CAGR, Awareness, U.S. FDA, Market, Valbenazine, Pharmaceutical industry, Disease, Growth

The report provides a complete analysis of Global Huntington's Disease Treatment Industry.

Key Points: 
  • The report provides a complete analysis of Global Huntington's Disease Treatment Industry.
  • The global huntington's disease treatment market will reach US$ 1,458.83 Million by 2027, from US$ 405.03 Million in 2021.
  • As per the analysis, Global Huntington's Disease Treatment Market Size is Expanding at a CAGR of 23.81% During 2021-2027.
  • Global Huntington's disease Treatment Industry was US$ 405.03 Million in 2021:
    Based on Treatment Type, the symptomatic treatment segment holds the significant market share.

Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results

Retrieved on: 
Freitag, Mai 6, 2022
PNS, Gabapentin, Pain, Shoulder, OH, Low back pain, GLOBE, NP-hardness, Safety, Time, SPR, Patient, Pain management, SPRINT, Knee, Quality of life, Medtech, Anticonvulsant, Chronic pain, Knee pain, Research, Risk, Therapy, Health insurance, Dentistry, MD

CLEVELAND, May 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation (PNS) in the management of chronic pain.

Key Points: 
  • CLEVELAND, May 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation (PNS) in the management of chronic pain.
  • The SPRINT PNS System is not intended to treat pain in the region innervated by the cranial and facial nerves.
  • SPR Therapeutics is a privately held medical device company, providing patients with a non-opioid, minimally invasive pain treatment option.
  • Our SPRINT PNS System fulfills a critical unmet need for a drug-free, surgery-free option for millions who suffer from chronic pain.